Power wheelchair — group 2 denied as experimental or investigational by UnitedHealthcare?

Under UnitedHealthcare's Commercial medical policy, mobility devices including manual wheelchairs, electric wheelchairs, transfer chairs, scooters/power-operated vehicles (POV), canes, and walkers are a covered health care service when medically necessary. The policy aligns with CMS LCD L33789, which establishes that the beneficiary must have a mobility limitation that significantly impairs his/her ability to participate in one or more mobility-related activities of daily living (MRADLs) such as toileting, feeding, dressing, grooming, and bathing in customary locations in the home — a limitation that prevents the beneficiary from accomplishing an MRADL entirely, places the beneficiary at heightened risk of morbidity or mortality, or prevents completing an MRADL within a reasonable time frame ; additionally, the mobility limitation cannot be sufficiently and safely resolved by an appropriately fitted cane or walker, and the beneficiary does not have sufficient upper extremity function to self-propel an optimally-configured manual wheelchair in the home to perform MRADLs during a typical day. Use of a power wheelchair must significantly improve the beneficiary's ability to participate in MRADLs and the beneficiary will use it in the home (for severe cognitive/physical impairments, participation in MRADLs may require caregiver assistance), and the beneficiary has not expressed an unwillingness to use a power wheelchair in the home. For a Group 2 standard PWC, a Group 2 PWC (K0820, K0821, K0822, K0823, K0824, K0825, K0826, K0827, K0828, K0829) is covered if all of the coverage criteria (a)-(e) for a PWC are met and the wheelchair is appropriate for the beneficiary's weight. For a Group 2 Single Power Option PWC, all coverage criteria (a)-(e) must be met, plus the beneficiary meets coverage criteria for a power tilt or recline seating system OR requires a drive control interface other than a hand or chin-operated standard proportional joystick (examples include head control, sip and puff, switch control) , and a specialty evaluation must be performed by a licensed/certified medical professional (PT, OT, or practitioner with rehab wheelchair training) with no financial relationship with the supplier, and the wheelchair must be provided by a supplier that employs a RESNA-certified Assistive Technology Professional (ATP) with direct, in-person involvement in the wheelchair selection. DME has a reasonable useful lifetime (RUL) of 5 years , and payment is made for only one wheelchair at a time; backup chairs are denied as not reasonable and necessary.

- **Document MRADL impact in detail**: Provide a clinician note specifying which MRADLs (toileting, feeding, dressing, grooming, bathing) the patient cannot complete or completes only with heightened morbidity/mortality risk, directly mapping to the LCD L33789 definition of a qualifying mobility limitation . - **Stepwise rule-out of lesser devices**: Submit PT/OT documentation explaining why a cane, walker, and optimally-configured manual wheelchair each fail — addressing strength, endurance, ROM, coordination, pain, or upper-extremity deformity per the LCD's enumerated upper-extremity assessment factors (strength, endurance, range of motion, coordination, pain, deformity or absence of one or both upper extremities) . - **Provide compliant face-to-face and WOPD**: Attach the dated face-to-face mobility examination note and the signed Standard Written Order before delivery; cite Final Rule 1713's requirement of a face-to-face encounter and Written Order Prior to Delivery as satisfied. - **Include RESNA ATP and independent specialty evaluation**: For Group 2 Single Power Option chairs, include both the ATP credential attestation and the independent PT/OT specialty evaluation, satisfying the requirement that a licensed PT/OT with no financial relationship to the supplier perform the specialty evaluation and that a RESNA-certified ATP have direct involvement in wheelchair selection . - **Demonstrate in-home use**: Document home assessment showing adequate access between rooms and maneuvering space, and explicitly state the device will be used in the home to meet the requirement that the beneficiary's home provides adequate access and that the power wheelchair will significantly improve the beneficiary's ability to participate in MRADLs in the home . - **Justify Group 2 over Group 1**: If denied as needing only a Group 1, document the patient's weight against capacity limits or, for Single Power Option, the medical necessity of power tilt/recline (e.g., pressure ulcer risk, inability to perform a functional weight shift) or alternative drive control interface per LCD L33789 Group 2 Single Power Option criteria including need for non-standard drive control such as head control, sip and puff, or switch control . - **Replacement vs. repair**: For replacement requests, document the 5-year RUL and that the existing chair cannot be repaired or no longer meets the patient's needs, citing the 5-year reasonable useful lifetime standard and UHC's allowance for upgrades when the member's condition changes (e.g., impaired function necessitates an upgrade to a power wheelchair from a manual one) .

## UHC "Experimental" Denials for Group 2 Power Wheelchairs Are Almost Always Misclassified

When UnitedHealthcare's Commercial or Individual Exchange plan denies a K0820–K0829 Group 2 power wheelchair as "experimental/investigational," the denial is almost certainly a misapplication of the Mobility Devices, Options, and Accessories medical policy. Group 2 PWCs are explicitly enumerated as covered codes in that policy, and the policy mirrors CMS LCD L33789 — which has been a settled, non-experimental Medicare benefit since 2006. An "experimental" rationale for a base Group 2 chair is a categorical contradiction of UHC's own published coverage language.

In practice, the "experimental" label is usually a downstream artifact of three things: (1) Optum/Naviguard utilization-management routing the file to a generic "new technology" template when the ATP-specified HCPCS includes a power option (single-power K0835–K0840 or multi-power K0848+); (2) missing or non-compliant specialty evaluation documentation (PT/OT or rehab-trained practitioner with no financial relationship with the supplier); or (3) the supplier not being credentialed with a RESNA-certified ATP in direct, in-person involvement. None of these are "experimental" issues — they are medical-necessity or supplier-credentialing issues, and conflating them shifts the burden incorrectly.

Pinto v. Aetna Life Ins. Co., 753 F.3d 1230 (10th Cir. 2014), is dispositive here: under ERISA, when a plan invokes an "experimental" exclusion, the insurer bears the burden of producing evidence the treatment is investigational under the plan's own definition. UHC cannot meet that burden for a HCPCS code its own policy lists as covered. Cite Pinto directly in the appeal.

Procedurally, fully insured commercial members get a 180-day internal appeal window and external IRO review under 29 CFR §2560.503-1; self-funded ERISA members get the same internal window plus the SPD's external review rights. For Medicare Advantage UHC members, the 42 CFR §422.566 organization determination/reconsideration pathway applies, and a Group 2 PWC denial must be tested against the binding LCD L33789 and PA-required HCPCS list — an MA plan cannot apply criteria more restrictive than Original Medicare under 42 CFR §422.101(b).

Tactical tip: Submit the appeal through the UHC Provider Portal (not the member portal) with the 7-Element Order, Detailed Product Description, specialty evaluation note, ATP attestation, and home assessment attached as a single PDF. In the cover letter, quote the exact bullet in UHC's Mobility Devices policy listing K0820–K0829 as covered, attach LCD L33789, and demand the medical director identify the peer-reviewed evidence supporting an "investigational" finding for a code the policy itself enumerates. If denied again, file simultaneously with your state DOI (or CMS for MA) — the contradiction between policy text and denial rationale is a one-page complaint.